MediciNova receives FDA approval to proceed with initial trial of ibudilast

Published September 28, 2010

MediciNova receives FDA approval to proceed with initial trial of ibudilast
MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported FDA’s approval to proceed with an initial trial of the company’s neurological drug candidate, ibudilast (MN-166/AV411), as a potential new pharmacotherapy for methamphetamine addiction.
Read more on News-Medical-Net